Archive | Clinical Trials

Novel Immunotherapy Shows Early Efficacy in Uveal Melanoma

IMCgp100, a novel immune-based treatment, demonstrated a 1-year survival rate of 73% (95% CI, 46%-88%) for patients with heavily pretreated, advanced uveal melanoma, which is nearly double the historical expectations for patients with the disease, according to lead investigator Richard D. Carvajal, MD.

Read the full story

Posted in Melanoma In The News, Clinical Trials

Neoadjuvant pembrolizumab appears effective for resectable melanoma

Neoadjuvant pembrolizumab followed by curative-intent resection and adjuvant therapy conferred 1-year recurrence-free survival of 55% among patients with stage III or stage IV resectable melanoma, according to study results presented at American Association for Cancer Research Annual Meeting.

Read the full story

Posted in Melanoma In The News, Clinical Trials

Fine tuning dosing schedules of targeted agents may improve responses in melanoma

Changing the schedule of targeted therapies has been shown to improve the response rate in a mouse model of melanoma, according to a report in Cancer Discovery.

Read the full story

Posted in Melanoma In The News, Clinical Trials

Drug combination targeting HSP90 and BRAF is safe and effective in advanced melanoma

Patients with advanced or metastatic melanoma have been able to live longer cancer-free lives because of several new therapies approved over the last decade, such as BRAF and MEK inhibitors.

Read the full story

Posted in Melanoma In The News, Clinical Trials

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories